latest update:
[TrialBase DB]

trial summary · NCT07808450

Nitazoxanide in Spontaneous Bacterial Peritonitis

Evaluation of Nitazoxanide as Adjunctive Therapy for Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis: A Randomized Controlled Clinical Trial Protocol

Trial record from the TrialBase DB dataset, status RECRUITING, condition SBP - Spontaneous Bacterial Peritonitis, sponsored by Tanta University. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07808450phase PHASE1/PHASE2enrollment 60start 2026-10-25

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Spontaneous bacterial peritonitis (SBP) is a life-threatening complication of liver cirrhosis characterized by infection of ascitic fluid in the absence of an evident intra-abdominal source. SBP occurs in approximately 10-30% of hospitalized cirrhotic patients with ascites and is associated with high short-term mortality despite advances in antimicrobial therapy. ¹˒² The pathogenesis of SBP is multifactorial and involves gut microbiota dysbiosis, increased intestinal permeability, bacterial translocation, and impaired host immune defenses. ³ Translocation of gut-derived bacteria and endotoxins, particularly lipopolysaccharides (LPS), activates systemic inflammatory pathways, promotes circulatory dysfunction, and predisposes patients to recurrent SBP episodes. ⁴˒⁵ Current management of SBP relies on empirical broad-spectrum antibiotics, most commonly third-generation cephalosporins, along with albumin infusion. ⁶ However, the increasing prevalence of multidrug-resistant organisms, recurrent SBP, and antibiotic-related adverse effects has created an urgent need for novel adjunctive or preventive strategies. ⁷ Nitazoxanide (NTZ) is a thiazolide derivative with broad-spectrum antibacterial, antiparasitic, and antiviral properties. In addition to its antimicrobial activity, NTZ has demonstrated anti-inflammatory effects, inhibition of nuclear factor-κB (NF-κB) signaling, and improved intestinal epithelial barrier integrity. ⁸˒⁹ Experimental data suggest that NTZ reduces gut permeability and systemic endotoxemia, mechanisms that are directly implicated in the development and …

Source record: https://clinicaltrials.gov/study/NCT07808450

Facts

registry idNCT07808450
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionSBP - Spontaneous Bacterial Peritonitis
sponsorTanta University
sponsor classOTHER
enrollment60
start date2026-10-25
primary completion2027-06-01
completion2027-06-01
results postednot reported

Conditions

  • SBP - Spontaneous Bacterial Peritonitis

Interventions

  • Nitazoxanide (NTZ)
  • Placebo

Countries

  • Egypt

Intervention types: DRUG

Work with this record